A Phase 3 interventional study of Bismuth added on triple therapy and Quadruple therapy in Helicobacter Eradication, sponsored by Reham Abdelkader Elkhouly. Completed at 1 site in Egypt. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-09-11.
Sponsored by Reham Abdelkader Elkhouly · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the study is to compare the efficacy of 2 different regimens of treatment of gastric bacteria (H pylori) these are: quadruple bismuth therapy and clarithromycin triple therapy with add-on bismuth, in eradicating H. pylori.
The secondary objective of the study is detection of adverse effects and treatment compliance in both regimens.
Study Design: Open label randomized controlled trial (RCT). Period of study:From September 2023 to September 2025 Participants: Among patients attending Gastroenterology clinic in Tropical medicine and infectious diseases department-Tanta university;200 patients with a confirmed diagnosis of helicobacter pylori infection were enrolled and allocated randomly in 2 equal parallel treatment arms.
Sample Size Calculation:
The sample size was calculated using a free online clinical trial calculator (ClinCalc.com) based on effect sizes from previous studies. A recent study in KSA reported an eradication rate of 78.3% for bismuth-based quadruple therapy [1]. Conversely, other studies have reported eradication rates of 88-94% [2] and 91.5-97.3% [3] for bismuth-based triple therapy. At a 95% confidence interval (α-error = 0.05) and 80% statistical power (β-error = 0.2), the minimum required sample size was 146 patients, allocated equally (73 per arm) [4]. To account for an anticipated attrition rate of approximately 30% a total of 200 patients (100 per group) were recruited.
Randomization and Allocation:
To ensure unbiased group assignment and concealment of the allocation sequence, a computer-generated randomization scheme was implemented. Block randomization was performed using a block size of 4, with computer-generated random permutations within each block. To minimize the risk of predicting the allocation sequence, the block size was randomly varied using blocks of 4 and 6 and was not disclosed to the treating investigator. Each enrolled patient was assigned a unique numerical identifier. The complete list of patient identifiers was then sorted in ascending order according to the generated random values. Based on this sorted sequence, the first 100 patients were allocated to Group I (Bismuth add on triple therapy), while the remaining 100 patients were assigned to Group II (Bismuth quadruple therapy). To maintain allocation concealment, the randomization sequence was generated by an independent investigator who was not involved in patient enrollment or outcome assessment. Group assignments were placed in sequentially numbered, opaque, sealed envelopes, which were opened just before starting treatment and after the enrolling physician confirmed patient eligibility and obtained written his/her informed consent.
All patients in the study will be subjected to the following:
Full history taking. Complete clinical examination. Laboratory Investigations including: complete blood picture, liver function tests and renal function tests.
Abdominal ultrasound. Confirm ation of H.pylori infection with either: quantification of H. pylori antigen in stool by ELISA, r upper gastrointestinal endoscopic biopsy and histopathological examination.
This is the only study on the registry with Reham Abdelkader Elkhouly as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
100 patients received oral triple therapy with add-on bismuth in the form of (Bismuth subcitrate 240 mg twice daily, Clarithromycin 500 mg twice daily, Amoxicillin 1gm twice daily, (PPI) Esomeprazole 40 mg twice daily for 2 weeks).
Drug: Bismuth added on triple therapy
100 patients received 14-day oral regimen comprising Bismuth subcitrate (240 mg twice daily), Doxycycline (100 mg twice daily), Metronidazole (500 mg three times daily), and Esomeprazole (40 mg twice daily).
Drug: Quadruple therapy
A 14-day oral regimen comprising Bismuth subcitrate (240 mg twice daily), Clarithromycin (500 mg twice daily), Amoxicillin (1 g twice daily), and the proton pump inhibitor (PPI) Esomeprazole (40 mg twice daily).
Also known as: modified bismuth quadruple therapy
Drug pages: Esomeprazole · Metronidazole · Bismuth tripotassium dicitrate · Tetracycline
14-day oral regimen comprising Bismuth subcitrate (240 mg twice daily), Doxycycline (100 mg twice daily), Metronidazole (500 mg three times daily), and Esomeprazole (40 mg twice daily).
Also known as: BQT
cure rate
cure rate in the experimental arm compared with cure rate in the comparator arm
Time frame: 4 weeks after the end of therapy
adverse events
adverse events of the two regimens in the two arms
Time frame: throughout the14 days of therapy
Plan to share: No — for patients confidentiality
Ran from Sep 2023 to primary completion in Sep 2025, 24 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.